Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith(Cleveland Metropolitan School District), Sean Parker(Northumbria Healthcare NHS Foundation Trust), J. Holcomb, David Elkayam(Merck & Co., Inc., Rahway, NJ, USA (United States)), John J. Condemi(Baylor College of Medicine), Eric Schenkel, Jonathan Corren(California Allergy and Asthma Medical Group), Lorcan McGarvey(Queen's University Belfast), Faisal Fakih, Thomas Murphy(Manchester Academic Health Science Centre), Alyn H. Morice(Castle Hill Hospital), Leon S. Greos, Ellen Sher, Mark H. Gotfried(Pulmonary Associates), Surinder S. Birring(King's College Hospital), Iftikhar Hussain(City University of Hong Kong), James Krainson, Shaila U Gogate, James H. Hull(Royal Brompton Hospital), Anthony Ford(Sunesis (United States)), Thomas B. Casale(University of South Florida), Jason Friesen, Jonathan Matz, Zhi Jin Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alan B. Goldsobel, Krishna M. Sundar, Selwyn Spangenthal, David I. Bernstein(Cincinnati Children's Hospital Medical Center), William R. Lumry(The University of Texas Southwestern Medical Center), William W. Storms(University of Pittsburgh), Yuping Li(Guangdong Province Women and Children Hospital), Wen‐Chi Wu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Kaplan(Duke University), Anthony Montanaro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Warner Carr(Asthma Association), Michael M. Kitt(Merck & Co., Inc., Rahway, NJ, USA (United States)), Gary Berman, Gregory Daniel Brooks, David Muccino(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mandel Sher(Florida Center for Gastroenterology), Gary N. Gross, Gary C. Steven, Niran J. Amar, James Good(Queen Elizabeth Hospital Birmingham), Bruce M. Prenner
The Lancet Respiratory Medicine
February 25, 2020
Cited by 224


Related Papers